한빛사 논문
Sehui Kima,b, Moon-Young Kima, Jaemoon Koha,b, Heounjeong Goc, Dong Soo Leed,e, Yoon Kyung Jeona,b,*, Doo Hyun Chunga,b,f,*
aDepartment of Pathology, Seoul National University Hospital, Seoul, Republic of Korea
bDepartment of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea
cDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
dDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
eDepartment of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
fDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
*Corresponding author.
Abstract
Pleomorphic carcinoma (PC) of the lung is a rare type of poorly differentiated non-small cell lung carcinoma (NSCLC) that belongs to sarcomatoid carcinoma (SC). It exhibits aggressive behaviour and resistance to chemotherapy and radiotherapy. Recently, immunotherapy targeting the programmed death-1 (PD-1)/PD ligand 1 (PD-L1) pathway has demonstrated favourable clinical outcomes in NSCLC. However, the expression patterns of PD-1-related molecules in pulmonary PC remain elusive.
PD-L1 and PD-L2 expression was estimated in 41 cases of PC using immunohistochemistry. CD8+ and PD-1+ tumour-infiltrating lymphocytes (TILs) were also evaluated.
PD-L1 and PD-L2 were highly expressed in pulmonary PCs (90.2% [37/41)]; 87.8% [36/41]). The amount of CD8+ or PD-1+ TILs and the ratio of PD-1+/CD8+ TILs in PC were higher in males, smokers and older patients. PD-L1-positive PCs were infiltrated by higher numbers of CD8+ TILs compared to PD-L1-negative cases (P = 0.006). Of note, PD-L1 expression in pulmonary PCs was significantly higher in sarcomatous areas than in the carcinomatous portion (P = 0.006). PC patients with a high ratio of PD-1+/CD8+ TILs showed a shorter progression-free survival (P = 0.036), whereas PD-L1 and PD-L2 expression had no prognostic implications.
Our study demonstrates that pulmonary PCs very frequently express PD-L1 and PD-L2. Moreover, their expression is higher in sarcomatous cells than in carcinomatous areas. Thus, targeting the PD-1/PD-L1 pathway may represent a potential therapeutic candidate for this aggressive tumour.
논문정보
관련 링크
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기